Tarlatamab-Durvalumab Maintenance for Extensive-Stage Small-Cell Lung Cancer.

Tarlatamab-durvalumab maintenance in extensive-stage small-cell lung cancer nearly halves death risk (HR 0.42) and extends median overall survival to 21.1 months.

• Why it matters: Outcomes for extensive-stage small-cell lung cancer remain poor after initial chemoimmunotherapy, and it was unclear whether adding tarlatamab to durvalumab during maintenance improves survival.
• What they did: In a phase 3 international open-label randomized trial, patients without progression after initial chemoimmunotherapy received tarlatamab-durvalumab or durvalumab; interim results were analyzed from randomization at maintenance start.
• The result: Median progression-free survival was 7.4 months with tarlatamab-durvalumab versus 1.9 months with durvalumab (HR 0.34; P<0.001), with grade 3+ adverse events in 46.8% vs 40.6% and cytokine release syndrome mainly grade 1–2 in nearly half.